# 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)

> **NCT02328027** · PHASE1,PHASE2 · TERMINATED · sponsor: **Advanced Accelerator Applications** · enrollment: 16 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Ankylosing Spondylitis

## Interventions

- **DRUG:** 99mTc-rhAnnexin V-128

## Key facts

- **NCT ID:** NCT02328027
- **Lead sponsor:** Advanced Accelerator Applications
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-11
- **Primary completion:** 2017-10-17
- **Final completion:** 2017-10-17
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328027, "99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02328027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*